Docetaxel/cisplatin therapy in myasthenia gravis with hypertension/diabetes

作者:Qi, Guoyan*; Xue, Yinping; Li, Yongzhao; Yang, Hongxia; Zhang, Xiaojing
来源:Open Medicine, 2017, 12(1): 403-408.
DOI:10.1515/med-2017-0058

摘要

Background: Therapeutic options for thymoma-associated myasthenia gravis (MG) patients complicated with hypertension and/or diabetes post thymectomy are often conventional steroids. As the prevalence of diabetes and hypertension globally increases, other therapeutic options for these patients are of great importance. Material/methods: 9 patients with thymoma-associated MG complicated with hypertension and/or diabetes after thymectomy were administered 75 mg/m2 of docetaxel and 70 mg/m2 of cisplatin on day 1. The treatment could be repeated at 3-week intervals, ranging from 1 to 4 cycles according to the status of the patients. Therapeutic efficacy and side effects were evaluated. Results: 2 patients were complicated with type 2 diabetes, 6 with hypertension, and 1 with both diabetes and hypertension. After docetaxel/cisplain therapy, the MG symptoms were markedly improved in all patients (2, complete remission; 3, basic remission; 3, marked improvement; 1, improvement). Acetylcholine receptor (AchR) antibody levels were decreased in 8 patients. Minor adverse effects were observed in 2 patients, 1 with Grade II gastrointestinal reaction, and the other with pulmonary infection. Conclusion: Docetaxel plus cisplatin might be an effective therapeutic option for thymoma-associated MG patients complicated with hypertension/diabetes post thymectomy without worsening thymoma and hypertension/diabetes.

  • 出版日期2017
  • 单位石家庄市第一医院